MSFT vs PFE: Which Is the Better Buy?
Side-by-side comparison of Microsoft Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
Microsoft Corporation · Technology
$429.25
-1.3% upside to fair value
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+28.6%).
PFE trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MSFT |
PFE |
| Current Price |
$429.25 |
$26.33 |
| Fair Value Estimate |
$423.82 |
$33.85 |
| Upside to Fair Value |
-1.3%
|
+28.6%
|
| Market Cap |
$3,187.4B |
$149.8B |
| Forward P/E |
26.8x
|
19.3x
|
| EV / EBITDA |
17.2x
|
12.9x
|
| Price / Sales |
10.4x
|
2.4x
|
| Price / FCF |
41.2x
|
16.5x
|
| Revenue Growth YoY |
+16.7%
|
-1.2%
|
| Gross Margin |
68.6%
|
70.3%
|
| Operating Margin |
46.7%
|
24.7%
|
| Return on Equity |
33.6%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.43%
|
6.06%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Microsoft Corporation is a leading technology company specializing in software infrastructure, cloud computing, and productivity solutions. The company benefits from a high-quality business model characterized by durable competitive moats including strong switching costs and intangible assets such as its brand and cloud infrastructure. Under CEO Satya Nadella's leadership since 2014, Microsoft ha…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
MSFT |
PFE |
| Zone Low |
$317.87 |
$25.39 |
| Zone High |
$360.25 |
$28.77 |
| In Buy Zone? |
No
|
Yes
|